

Contents

List of contributors	VII
<i>Ruth Duncan and Francesco M. Veronese</i>	
Preface: PEGylated protein conjugates: A new class of therapeutics for the 21st century	1
<i>Francesco M. Veronese, Anna Mero and Gianfranco Pasut</i>	
Protein PEGylation, basic science and biological applications	11
<i>Gian Maria Bonora and Sara Drioli</i>	
Reactive PEGs for protein conjugation	33
<i>Ji-Won Choi, Antony Godwin, Sibulalan, Penny Bryant, Yuehua Cong, Estera Pawlisz, Manuchehr Porssa, Norbert Rumpf, Ruchi Singh, Keith Powell and Steve Brocchini</i>	
Rebridging disulphides: site-specific PEGylation by sequential bis-alkylation	47
<i>Mauro Sergi, Francesca Caboi, Carlo Maullu, Gaetano Orsini and Giancarlo Tonon</i>	
Enzymatic techniques for PEGylation of biopharmaceuticals	75
<i>Angelo Fontana, Barbara Spolaore, Anna Mero and Francesco M. Veronese</i>	
The site-specific TGase-mediated PEGylation of proteins occurs at flexible sites	89
<i>Conan J. Fee</i>	
Protein conjugates purification and characterization	113
<i>Rob Webster, Victoria Elliott, B. Kevin Park, Donald Walker, Mark Hankin and Philip Taupin</i>	
PEG and PEG conjugates toxicity: towards an understanding of the toxicity of PEG and its relevance to PEGylated biologicals	127
<i>Jonathan K. Armstrong</i>	
The occurrence, induction, specificity and potential effect of antibodies against poly(ethylene glycol)	147

<i>Graham Molineux</i> Pegfilgrastim – designing an improved form of rmetHuG-CSF	169
<i>Rory F. Finn</i> PEGylation of human growth hormone: strategies and properties	187
<i>Gianfranco Pasut</i> PEGylated α interferons: two different strategies to achieve increased efficacy	205
<i>Michael S. Hershfield, John S. Sundry, Nancy J. Ganson and Susan J. Kelly</i> Development of PEGylated mammalian urate oxidase as a therapy for patients with refractory gout	217
<i>Andrew M. Nesbitt, Sue Stephens and Elliot K. Chartash</i> Certolizumab pegol: a PEGylated anti-tumour necrosis factor alpha biological agent	229
<i>Anna Mero, Gianfranco Pasut and Francesco M. Veronese</i> PEG: a useful technology in anticancer therapy	255
<i>Tacey X. Viegas and Francesco M. Veronese</i> Regulatory strategy and approval processes considered for PEG-drug conjugates and other nanomedicines	273
Index	283